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chondrocyte cultures, either from the normal donors or from the 
OA patients, with I L-1 I~ (10 ng/ml, incubation periods ranging from 
5 min to 16 h), TNF-~ (20 ng/ml, 6 h), TGF-I~ (10 ng/ml, 2, 6 and 
16 h-incubation periods) or IGF-1 (100 ng/ml, 6 h) did not change 
NOS I protein levels relatively to the respective controls. 
Conclusions: The results obtained show that OA chondrocytes 
are deficient in NOS I relatively to normal cells and also indicate 
that this protein is not regulated by any of the anabolic or catabolic 
stimuli n the conditions tested. Our previous results showed that, 
in bovine chondrocytes, NOS I is rapidly degraded in response to 
IL-1 and that NO inhibits IL-1 -induced NF-KB activation and iNOS 
expression, indicating that NO participates in a regulatory mech- 
anism that prevents accidental or inappropriate NF-KB activation. 
The absence of the NOS I protein in human OA chondrocytes, 
reported here, suggests that the regulatory mechanism identified 
in normal bovine chondrocytes does not opperate in human OA 
chondrocytes. Thus, the absence of NOS I may contribute to the 
impaired regulation of NF-KB activation and of the expression of 
its target genes, namely, several inflammation-related genes and 
matrix metalloproteinases that contribute to the development and 
progression of arthritic diseases. 
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Few structure-modifying drugs have been used to date for OA 
treatment, and most commonly used medications are symptom- 
modifying drugs, such as NSAIDs. Although both treatments have 
been shown to be effective for improving pain and disability, their 
effects on cartilage and synovial metabolism remain poorly stud- 
ied. 
Aim of the study: To compare the effect of glucosamine sulfate 
(GS) to that seen for different anti-OA drugs, such as NSAI Ds and 
other nutraceuticals on the activation of several proinflammatory 
and structural mediators in OA chondrocytes and synoviocytes in 
culture. 
Methods: Chondrocytes and synoviocytes were obtained from 
joint specimens of OA patients who underwent otal knee replace- 
ment. Using quiescent cells stimulated with 10 U/ML IL-11~, the ef- 
fects of GS (1 mg/ml), meloxicam (MXC, 10-6M), diclofenac (DCF, 
10-6M), indomethacin (IND, 10-6M), chondroitin sulphate (CS, 
1 mg/ml), diacerhein (DC, 10-5M), and N-acetylcysteine (NAC, 
2 mM) on prostaglandin (PG) E2 production, cyclooxigenase- 
2 (COX-2) expression, nitric oxide (NO) synthesis, metallopro- 
teinase (MMP)-I and MMP-13 presence and nuclear factor kappa 
B (NFKB) activation were studied. 
Results: With IL-11~ stimulation, an increased presence of all of 
these mediators was noted, except for NO synthesis in synovio- 
cytes. After stimulation, PGE2 synthesis was significantly inhib- 
ited by GS (up to 60%) and NSAIDs (100%) in both cell types, 
and also by DC (45%) in chondrocytes and by NAC (65%) in 
synoviocytes. COX-2 synthesis, measured by western-blot tech- 
niques, was also inhibited in both cell types by incubation with 
GS (up to 60%) or NSAIDs (up to 40%), while NAC (50%) also 
diminished COX-2 in synoviocytes. In relation to the increase in 
NO synthesis in chondrocytes evoked by IL-11~, only GS (75%), 
DC (30%) and CS (20%) were able to inhibit it, and no effect was 
noted for NSAIDs or NAC. One of the possible cellular mecha- 
nisms involved in the activation of these proinflammatory events 
has also been studied. NFKB activation was only inhibited by 
GS (60%), DC (75%) and DCF (75%) in chondrocytes, and by 
GS (45%), DC (69%), CS (65%)and DCF (60%) in synoviocytes. 
MMP-1 and -13 activation were inhibited only in chondrocytes 
by GS (65% and 75%, respectively). Between other nutraceuti- 
cals, only CS (60%) diminished MMP-1 activity in chondrocytes. 
However, NSAID presence did not modify or even super-induced 
MMP1 and -13 synthesis in both cell types. 
Conclusion: GS inhibits the synthesis of proinflammatory and 
structural mediators in OA chondrocytes and synoviocytes tim- 
ulated by IL-11~. The presence of other nutraceticals only partially 
controlled some of these mediators. NSAIDs were able to signif- 
icantly inhibit proinflammatory pathways, while structural media- 
tors were unchanged or even activated. Our study supports the 
role of GS as a symptom and structure-modifying drug. 
P310 
INFLUENCE OF PLATELET RICH PLASMA IN HUMAN 
CHONDROCYTE 
H Mitsuyama 1,2, S Mishima 1 , S Kondo 1 , N Ishiguro 1 , D Amiel 2 
l Orthopaedic Surgery, Nagoya University Graduate School of 
Medicine, Nagoya, Aichi, Japan; 2Orthopaedics, University of 
California, San Diego, San Diego, CA 
Aim of Study: The aim of the present study is to investigate the 
effects of platelet rich plasma (PRP) on proliferation and rediffer- 
entiation of cultivated human chondrocytes. 
Methods: Whole blood and knee joint cartilage were supplied 
from 10 adult donors after informed consent. Chondrocytes were 
isolated by enzyme digestion from cartilage and suspended nu- 
trient mixture medium with 10% fetal bovine serum (FBS). When 
cultured dishes became near confluent, cells were passed only 
one time. Blood was drawn into a bag containing anticoagulant 
and centrifuged twice to obtain PRP. By mixing calcium gluconate 
and thrombin to PRP, platelets released growth factors from their 
granule and PRP gel was obtained. MTT assay was used for 
the quantitative determination of cellular proliferation. We inves- 
tigated the effect of different PRP concentrations on chondro- 
cyte proliferation and also performed a time course experiment 
to establish a growth curve of cells cultivated in control condi- 
tion (30% platelet poor plasma) or in 30% PRP. All MTT assays 
were performed using serum-free medium. Redifferentiation of 
cultivated chondrocyte is associated with increased glycosamino- 
glycans (GAGs) and type II collagen expression. Alcian blue and 
anti-type II collagen antibodies were used for histochemical and 
immunohistochemical examinations to analyze the influence of 
PRP on redifferentiation. 
Results: Cell proliferation of human chondrocytes was sensitive 
to PRP. The increase was dose dependent, and MTT values in- 
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Fig. 1. MTT assay of human chondrocyte. 
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induced a marked increase of MTT values compared to control 
culture. Time course experiments performed with chondrocytes 
cultivated in 30% platelet poor plasma (PPP) or in 30% PRP 
showed that PRP promoted an increase of MTT values that was 
observed for the entire 12 day testing period. 
In PRP gel, cell bodies and pericellular matrix were stained more 
strongly with alcian blue compared with that in PPP gel. Like- 
wise, immunoreactivity to the anti-type II collagen antibodies was 
shown more certainly in PRP gel. Histochemical and immuno- 
histochemical examinations demonstrated that cultivated chon- 
drocytes can easily lose their phenotype ven in passage 1 cells, 
however PRP enhances redifferentiation ofdedifferentiated chon- 
drocytes. 
Conclusion: 30% PRP promotes human chondrocyte prolifer- 
ation. Cells expanded with 30% PRP can express chondrocyte 
phenotype. It is suggested that PRP gel provides an invaluable 
source of growth factors for human chondrocyte proliferation and 
redifferentiation, and could serve as a scaffold for autologous 
chondrocyte implantation that has potential availability for repair 
of osteoarthritis with chondral defects. 
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Study aims: Granulin-epithelin precursor (GEP) was identified as 
a COMP-binding protein in a functional genetic screen. GEP is a 
secreted growth facotor. It contributes to tumorigenesis in diverse 
cancers. The aim of this study was to characterize the interaction 
between GEP and COMP and to investigate their potential as 
therapeutic targets in musculoskeletal tumors. 
Methods: Yeast two hybrid (Y2H) Library Screen. Functional do- 
mains of COMP were used as bait to screen rat brain pPC86 
cDNA library. In VitroBinding Assay - Glutathione-Sepharose 
beads preincubated with either GST or GST-EGF domain of 
COMP were incubated with purified His-tagged GEP. Bound pro- 
teins were detected with anti-His antibodies. Proliferation Assay 
- rat chondrosarcoma cells (RCS) were transfected with empty 
vector, construct encoding GEP and constructs encoding GEP 
and COMP respectively and selected with G418. Cell prolifera- 
tion was assayed by seeding lx105 cells into 6-well plates. Cells 
were harvested and viable cells were counted. 
Results: Isolation of GEP as a COMP binding partner. To better 
understand the biological functions of COME we performed Y2H 
screen. Briefly, a Y2H rat cDNA library was screened with the 
construct encoding the EGF-like repeats of COME We screened 
approximately 2.5 million clones and identified 12 positive clones. 
Two positive clones among them encoded two N-terminal trun- 
cated mutants (a.a. 228-588; a.a.334-588) of GEP (Accession 
#NM_017113.1). 
COMP directly binds to GEP - To verity the interaction between 
COMP and GEP which was first identified in yeast, a GST pull- 
down assay was performed to test whether EGF-like domain of 
COMP binds to the C-terminal of GEP (a.a.228-588) in vitro. 
GST did not pull down GEP protein, whereas GST-EGF efficiently 
pulled down GEP protein, indicating binding of COMP to GEP in 
vitro. 
COMP enhances the GEP-mediated stimulation of chondrosar- 
coma cellproliferation - Overexpression of COMP alone produce 
negligible effects on tumor cell growth; whereas overexpression 
of GEP resulted in a clear increase in cell proliferation by 43% in 
day 3 and robust stimulation was observed in day 4 (1.8 fold) and 
day 5 (3.5 folds). Intriguingly this GEP-mediated stimulation was 
further enhanced by co-expression of COMP. The enhancement 
was observed since day 2 (2.3 folds) and remained significant 
with slightly going down (2.1 folds in day 3, 1.7 folds in day 4 and 
1.5 folds in day 5 respectively). 
Conclusion: We reported a novel interaction between a muscu- 
Ioskeletal tissues-specific extracellular matrix COMP protein and 
a GEP growth factor and the enhancement of GEP-stimulated 
chondrosarcoma growth by COME Since GEP was found to pro- 
mote the growth, invasion and metastasis of several tumors, our 
findings demonstrate that COMP may function as an important 
mediator of musculoskeletal tumors via associating with GEP, 
presenting GEP to its membrane receptor and regulating GEP- 
mediated signal transduction and gene regulation pathways. 
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Although OA is not considered an inflammatory arthropathy, it is 
now clear that inflammatory modulators are prominent players in 
pathogenesis of the disease. Overproduction of the immunomod- 
ulator prostaglandin E2 (PGE2) and of the rate-limiting enzyme 
involved in its biosynthesis, cyclooxygenase-2 (COX-2), by OA 
and RA chondrocytes and human synovial fibroblasts (HSFs) 
have made this enzyme the subject of intense interest. While 
an impressive number of regulatory mechanisms implicated in 
COX-2 gene expression are now known, the mechanisms regu- 
lating COX-2 catalytic activity are still not fully understood. We 
have uncovered a novel control mechanism involving limited pro- 
teolysis of the COX-2 protein that regulates intrinsic cyclooxy- 
genase/peroxidase activities and ultimately the biosynthesis of 
PGE2. IL-11~ stimulation of human synovial fibroblasts (HSFs), 
chondrocytes and macrophages induced the synthesis of COX- 
2 protein and its coincident proteolysis into a series of stable, 
distinct immunoreactive fragments (i.e., 66, 42-44, 34-36 and 28 
kDa) that accumulated in a time-dependent manner. The induc- 
tion of PGE2 synthesis (i.e., COX-2 activity) in HSFs coincided 
with the start of COX-2 fragmentation. Regression analysis con- 
firmed a direct linear correlation (R2=0.91) between PGE2 se- 
cretion and the timing and degree of COX-2 proteolysis in IL-11~- 
treated HSFs, as well as cells treated with other arthropathologi- 
cally relevant pro-inflammatory c tokines (i.e., TNF-alpha, IL-17). 
Cleavage positions within COX-2 were confined to the catalytic 
domain as confirmed by mass-spectrometry (MALDI-TOF). Phar- 
macological inhibition of induced COX-2 activity by a variety of 
non-selective and COX-2-specific NSAIDs abrogated proteolysis. 
NSAID-mediated inhibition of proteolysis was not mechanistically 
related to direct enzymatic inactivation of COX-2, as shown by 
the reduction in COX-2 cleavage and PGE2 synthesis by (R)- 
flurbiprofen, which does not inhibit COX-2 and is not efficiently 
isomerized to the active (S)-flurbiprofen. These results pointed 
to the involvement of NSAID-sensitive proteolytic enzymes in the 
COX-2 fragmentation process, a hypothesis upported by the cor- 
related reduction in COX-2 cleavage and PGE2 synthesis by both 
g-secretase and cysteine/calpain protease inhibitors. Our results 
suggest that nascent COX-2 is initially in an enzymatically latent 
form and must be activated by limited proteolysis for full biosyn- 
thetic activity. 
